Lack of association between TNF-α promoter polymorphisms and multiple myeloma: A meta-analysis

Leukemia Research

Volumn 37, Issue 1, 2013, Pages 50-57

  Li, Bing ^a   Wang, Xiao Dan ^b   Sun, Xiaolei ^a   Ma, Jianxiong ^a   Yang, Yang ^a   Ma, Xinlong ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b TIANJIN HUANHU HOSPITAL   (China)

Author keywords

Gene polymorphisms; Meta analysis; Multiple myeloma; Sub group analysis; TNF promoter 238; TNF promoter 308

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CHINESE; EUROPEAN AMERICAN; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROMOTER REGION; TUMOR NECROSIS FACTOR ALPHA GENE;

AGED; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; PUBLICATION BIAS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84870871586     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.08.027     Document Type: Article

References (44)

1. Chan K.F., Siegel M.R., Lenardo J.M. Signaling by the TNF receptor superfamily and T cell homeostasis. Immunity 2000, 13:419-422.
2. Li C., Wang G., Gao Y., Liu L., Gao T. TNF-alpha gene promoter -238G>A and -308G>A polymorphisms alter risk of psoriasis vulgaris: a meta-analysis. J Invest Dermatol 2007, 127:1886-1892.
3. Nedospasov S.A., Udalova I.A., Kuprash D.V., Turetskaya R.L. DNA sequence polymorphism at the human tumor necrosis factor (TNF) locus. Numerous TNF/lymphotoxin alleles tagged by two closely linked microsatellites in the upstream region of the lymphotoxin (TNF-beta) gene. J Immunol 1991, 147:1053-1059.
4. Wilson A.G., di Giovine F.S., Blakemore A.I., Duff G.W. Single base polymorphism in the human tumour necrosis factor alpha (TNF alpha) gene detectable by NcoI restriction of PCR product. Hum Mol Genet 1992, 1:353.
5. Pociot F., D'Alfonso S., Compasso S., Scorza R., Richiardi P.M. Functional analysis of a new polymorphism in the human TNF alpha gene promoter. Scand J Immunol 1995, 42:501-504.
6. Li B., Wang P., Li H. The association between TNF-alpha promoter polymorphisms and ankylosing spondylitis: a meta-analysis. Clin Rheumatol 2010, 29:983-990.
7. Oregon-Romero E., Vazquez-Del M.M., Ruiz-Quezada S.L., Navarro-Hernandez R.E., Rangel-Villalobos H., Martinez-Bonilla G., et al. Tumor necrosis factor alpha -308 and -238 polymorphisms in rheumatoid arthritis. Association with messenger RNA expression and sTNF-alpha. J Investig Med 2008, 56:937-943.
8. Neben K., Mytilineos J., Moehler T.M., Preiss A., Kraemer A., Ho A.D., et al. Polymorphisms of the tumor necrosis factor-alpha gene promoter predict for outcome after thalidomide therapy in relapsed and refractory multiple myeloma. Blood 2002, 100:2263-2265.
9. Shapiro-Shelef M., Calame K. Plasma cell differentiation and multiple myeloma. Curr Opin Immunol 2004, 16:226-234.
10. Carter A., Merchav S., Silvian-Draxler I., Tatarsky I. The role of interleukin-1 and tumour necrosis factor-alpha in human multiple myeloma. Br J Haematol 1990, 74:424-431.
11. Palumbo A., Facon T., Sonneveld P., Blade J., Offidani M., Gay F., et al. Thalidomide for treatment of multiple myeloma: 10 years later. Blood 2008, 111:3968-3977.
12. Zheng C., Huang D.R., Bergenbrant S., Sundblad A., Osterborg A., Bjorkholm M., et al. Interleukin 6, tumour necrosis factor alpha, interleukin 1beta and interleukin 1 receptor antagonist promoter or coding gene polymorphisms in multiple myeloma. Br J Haematol 2000, 109:39-45.
13. Du J., Yuan Z., Zhang C., Fu W., Jiang H., Chen B., et al. Role of the TNF-alpha promoter polymorphisms for development of multiple myeloma and clinical outcome in thalidomide plus dexamethasone. Leuk Res 2010, 34:1453-1458.
14. Kadar K., Kovacs M., Karadi I., Melegh B., Pocsai Z., Mikala G., et al. Polymorphisms of TNF-alpha and LT-alpha genes in multiple myeloma. Leuk Res 2008, 32:1499-1504.
15. Brown E.E., Lan Q., Zheng T., Zhang Y., Wang S.S., Hoar-Zahm S., et al. Common variants in genes that mediate immunity and risk of multiple myeloma. Int J Cancer 2007, 120:2715-2722.
16. Au W.Y., Fung A., Wong K.F., Chan C.H., Liang R. Tumor necrosis factor alpha promoter polymorphism and the risk of chronic lymphocytic leukemia and myeloma in the Chinese population. Leuk Lymphoma 2006, 47:2189-2193.
17. Morgan G.J., Adamson P.J., Mensah F.K., Spink C.F., Law G.R., Keen L.J., et al. Haplotypes in the tumour necrosis factor region and myeloma. Br J Haematol 2005, 129:358-365.
18. Iakupova E.V., Grinchuk O.V., Kalimullina D., Bakirov B.A., Galimova R.R., Makarova O.V., et al. [Molecular genetic analysis of the interleukin 6 and tumor necrosis factor alpha gene polymorphisms in multiple myeloma]. Mol Biol (Mosk) 2003, 37:420-424.
19. Davies F.E., Rollinson S.J., Rawstron A.C., Roman E., Richards S., Drayson M., et al. High-producer haplotypes of tumor necrosis factor alpha and lymphotoxin alpha are associated with an increased risk of myeloma and have an improved progression-free survival after treatment. J Clin Oncol 2000, 18:2843-2851.
20. Martino A., Buda G., Maggini V., Lapi F., Lupia A., Di Bello D., et al. Could age modify the effect of genetic variants in IL6 and TNF-alpha genes in multiple myeloma?. Leuk Res 2012, 36:594-597.
21. Mantel N., Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959, 22:719-748.
22. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188.
23. Higgins J.P., Thompson S.G. Quantifying heterogeneity in a meta-analysis. Stat Med 2002, 21:1539-1558.
24. Higgins J.P., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560.
25. Egger M., Davey S.G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
26. Katz J., Gong Y., Salmasinia D., Hou W., Burkley B., Ferreira P., et al. Genetic polymorphisms and other risk factors associated with bisphosphonate induced osteonecrosis of the jaw. Int J Oral Maxillofac Surg 2011, 40:605-611.
27. Zhao H.Y., Chen Y.X. Review of relationship between tumor necrosis factor genetic polymorphism and hematological malignancies. Ai Zheng 2003, 22:216-220.
28. Du J., Yuan Z.G., Zhang C.Y., Fu W.J., Jiang H., Chen B.A., et al. Effect of TNF-alpha gene polymorphism on outcome of thalidomide-based regimens for multiple myeloma. Zhonghua Xue Ye Xue Za Zhi 2009, 30:649-653.
29. Dring A.M., Davies F.E., Rollinson S.J., Roddam P.L., Rawstron A.C., Child J.A., et al. Interleukin 6, tumour necrosis factor alpha and lymphotoxin alpha polymorphisms in monoclonal gammopathy of uncertain significance and multiple myeloma. Br J Haematol 2001, 112:249-251.
30. Hideshima T., Chauhan D., Schlossman R., Richardson P., Anderson K.C. The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene 2001, 20:4519-4527.
31. Urashima M., Ogata A., Chauhan D., Hatziyanni M., Vidriales M.B., Dedera D.A., et al. Transforming growth factor-beta1: differential effects on multiple myeloma versus normal B cells. Blood 1996, 87:1928-1938.
32. Gupta D., Treon S.P., Shima Y., Hideshima T., Podar K., Tai Y.T., et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 2001, 15:1950-1961.
33. Chauhan D., Uchiyama H., Akbarali Y., Urashima M., Yamamoto K., Libermann T.A., et al. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood 1996, 87:1104-1112.
34. Wilson A.G., Symons J.A., McDowell T.L., McDevitt H.O., Duff G.W. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci USA 1997, 94:3195-3199.
35. Abraham L.J., Kroeger K.M. Impact of the -308 TNF promoter polymorphism on the transcriptional regulation of the TNF gene: relevance to disease. J Leukoc Biol 1999, 66:562-566.
36. Bouma G., Crusius J.B., Oudkerk P.M., Kolkman J.J., von Blomberg B.M., Kostense P.J., et al. Secretion of tumour necrosis factor alpha and lymphotoxin alpha in relation to polymorphisms in the TNF genes and HLA-DR alleles. Relevance for inflammatory bowel disease. Scand J Immunol 1996, 43:456-463.
37. Wilson A.G., de Vries N., Pociot F., di Giovine F.S., van der Putte L.B., Duff G.W. An allelic polymorphism within the human tumor necrosis factor alpha promoter region is strongly associated with HLA A1, B8, and DR3 alleles. J Exp Med 1993, 177:557-560.
38. Meenagh A., Williams F., Ross O.A., Patterson C., Gorodezky C., Hammond M., et al. Frequency of cytokine polymorphisms in populations from western Europe, Africa, Asia, the Middle East and South America. Hum Immunol 2002, 63:1055-1061.
39. Delaney N.L., Esquenazi V., Lucas D.P., Zachary A.A., Leffell M.S. TNF-alpha, TGF-beta, IL-10, IL-6, and INF-gamma alleles among African Americans and Cuban Americans. Report of the ASHI Minority Workshops: Part IV. Hum Immunol 2004, 65:1413-1419.
40. Parker M., Anand J.K., Myles J.W., Lodwick R. Proximal femoral fractures: prevalence in different racial groups. Eur J Epidemiol 1992, 8:730-732.
41. Lane D.A., Lip G.Y., Beevers D.G. Ethnic differences in cancer incidence and mortality: the Birmingham Factory Screening Project. QJM 2007, 100:423-431.
42. Tiret L. Gene-environment interaction: a central concept in multifactorial diseases. Proc Nutr Soc 2002, 61:457-463.
43. Pan J.W., Cook L.S., Schwartz S.M., Weis N.S. Incidence of leukemia in Asian migrants to the United States and their descendants. Cancer Causes Control 2002, 13:791-795.
44. Bergsagel D. The incidence and epidemiology of plasma cell neoplasms. Stem Cells 1995, 13(Suppl. 2):1-9.